![]() |
市場調查報告書
商品編碼
1764857
2031年北美動脈血氣分析試劑盒市場預測 - 區域分析 - 按注射器類型、種類、用途、應用、針頭規格、注射器容量和最終用戶North America Arterial Blood Gas Kits Market Forecast to 2031 - Regional Analysis - by Syringe Type, Type, Usage, Application, Needle Gauge, Syringe Volume, and End User |
2023 年北美動脈血氣試劑盒市值為 3,01,799.63 千美元,預計到 2031 年將達到 5,34,661.28 千美元;預計 2023 年至 2031 年的複合年成長率為 7.4%。
呼吸系統疾病發生率上升推動北美動脈血氣分析試劑盒市場
氣喘、慢性阻塞性肺病 (COPD) 和肺炎等呼吸系統疾病給世界各國的公共醫療系統帶來了沉重的負擔。感染、吸煙和遺傳因素都可能導致嚴重的呼吸系統併發症。慢性阻塞性肺病 (COPD) 是全球第四大死因,2021 年導致 350 萬人死亡,約佔全球死亡總數的 5%。 70 歲以下族群中約 90% 的 COPD 相關死亡發生在中低收入國家 (LMIC)。 2021 年,美國肺臟協會將 COPD 列為美國第三大死因,當年有超過 1,640 萬人被診斷出患有 COPD。根據美國氣喘和過敏基金會的數據,2022 年美國約有 2,600 萬人患有氣喘。聯合國國際兒童緊急基金會 (UNICEF) 表示,每年每 10 萬名兒童中約有 1,400 名(即每 71 名兒童中就有 1 名)被診斷出患有肺炎。呼吸系統疾病患者通常會出現呼吸困難和缺氧。動脈血氣 (ABG) 測試用於測量溶解在血液中的氧氣和二氧化碳氣體。該測試是急性和慢性呼吸系統疾病患者護理的基礎。因此,急性和慢性呼吸系統疾病發病率的激增推動了對動脈血氣檢測試劑盒的需求。
北美動脈血氣試劑盒市場概覽
根據美國心臟衰竭協會 (HFSA) 於 2023 年啟動的 HF Stats (SM) 計劃,預計每 4 人中就有 1 人 (約 25%) 會在一生中患上 HF,高於先前估計的每 5 人中 1 人 (約 20%)。根據 HFSA 資料庫 HF Stats,約有 670 萬 20 歲以上的美國人患有 HF,預計到 2030 年患病人數將上升到 850 萬人。 HF 的終身風險已增加至 24%,即預計每 4 人中就有 1 人會在一生中罹患 HF。根據美國氣喘和過敏基金會的數據,2022 年美國約有 2,600 萬人患有氣喘,氣喘是世界上最常見的呼吸系統疾病之一。呼吸道感染會導致更嚴重的疾病,導致住院或死亡。由於與年齡相關的問題,例如虛弱和免疫衰老,老年人的死亡率高於年輕人。氣喘是老年人最常見的呼吸系統疾病之一。根據 2020 年人口普查,2020 年美國老年人口達到 5,580 萬人(佔總人口的 16.8%),預計 2012 年至 2050 年期間老年人口將大幅上升。這些人需要更了解呼吸系統疾病對其健康的影響,因為患有呼吸系統疾病的患者通常會因缺氧而出現呼吸問題。動脈血氣分析以分氧壓 (PaO2) 和分二氧化碳壓 (PaCO2) 的形式評估患者動脈血中的溶解氧和二氧化碳含量。 PaCO2 提供有關通氣狀態(急性或慢性呼吸衰竭)的資訊,而 PaO2 則提供有關氧合狀態的資訊。需要動脈血氣分析的慢性疾病(包括呼吸衰竭、急性呼吸窘迫症候群 (ARDS)、氣喘、糖尿病酮症酸中毒、腎小管性酸中毒、心臟衰竭 (HF) 和先天性代謝性疾病)的盛行率日益上升,是美國在動脈血氣試劑盒市場佔據最大佔有率的主要原因。此外,美國在技術進步方面的穩固地位也顯著促進了各種動脈血氣試劑盒及相關技術的普及。
北美動脈血氣試劑盒市場收入及預測(2031 年)(千美元)
北美動脈血氣試劑盒市場細分
北美動脈血氣分析試劑盒市場分為注射器類型、類型、用途、應用、針頭規格、注射器容量、最終用戶和國家。
根據注射器類型,北美動脈血氣分析試劑盒市場分為魯爾滑動注射器和魯爾鎖注射器。魯爾鎖注射器在2023年佔據了較大的市場佔有率。
就類型而言,北美動脈血氣分析儀市場分為帶通氣孔型和非帶通氣孔型。 2023年,帶通氣孔型佔據了較大的市場佔有率。
根據用途,北美動脈血氣分析試劑盒市場分為預設柱塞式和手動抽吸式。預設柱塞式在2023年佔據了較大的市場佔有率。
根據應用,北美動脈血氣分析試劑盒市場分為體外診斷和電解質分析。 2023年,體外診斷領域佔據了更大的市場。此外,體外診斷領域也細分為血氣pH值、血氧含量和其他。
就針頭規格而言,北美動脈血氣分析試劑盒市場細分為小於23G、23G至25G和大於25G。 2023年,23G至25G針頭佔據了最大的市場。
根據注射器容量,北美動脈血氣分析試劑盒市場細分為1毫升、3毫升和其他容量。 2023年,3毫升注射器佔據了最大的市場佔有率。
按最終用戶分類,北美動脈血氣分析試劑盒市場分為醫院和診所、診斷實驗室和其他。 2023年,醫院和診所佔據了最大的市場。
根據國家/地區,北美動脈血氣試劑盒市場細分為美國、加拿大和墨西哥。 2023年,美國佔據了北美動脈血氣試劑盒市場的主導地位。
Radiometer Medical ApS、Vyaire Medical Inc、Opti Medical Systems、Siemens Healthineers AG、AdvaCare Pharma USA LLC、Becton Dickinson and Co、ICU Medical Inc、SunMed Group Holdings LLC (AirLife)、Trudell Healthcare Solutions Inc、SARSTEDT AG & Co KG 和樂普醫療試劑盒市場領先的動脈血氣試劑盒市場領先的動脈血氣試劑盒市場領先的動脈血氣試劑盒市場領先的動脈血氣試劑盒市場領先的動脈血氣試劑盒市場領先的動脈血氣。
The North America arterial blood gas kits market was valued at US$ 3,01,799.63 thousand in 2023 and is expected to reach US$ 5,34,661.28 thousand by 2031; it is estimated to register a CAGR of 7.4% from 2023 to 2031.
Increasing Incidence of Respiratory Diseases Fuels North America Arterial Blood Gas Kits Market
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia lead to a huge burden on public healthcare systems in various countries across the world. Infections, smoking, and genetic factors can cause serious respiratory complications. Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death globally, resulting in 3.5 million deaths in 2021, which represents about 5% of all deaths worldwide. Approximately 90% of COPD-related deaths among individuals under 70 years of age occur in low- and middle-income countries (LMIC). In 2021, the American Lung Association ranked COPD third among the leading causes of death in the US, and over 16.4 million people are diagnosed with the condition that year. As per the Asthma and Allergy Foundation of America, ~26 million people in the US had asthma in 2022. The United Nations International Children's Emergency Fund (UNICEF) stated that nearly 1,400 per 100,000 children, i.e., 1 case per 71 children, are diagnosed with pneumonia every year. Breathing issues and oxygen shortages are common in patients suffering from respiratory disorders. Arterial blood gas (ABG) tests are performed to measure oxygen and carbon dioxide gases dissolved in blood. The test serves as a basis of care delivered to patients suffering from acute and chronic respiratory disease. Thus, the surging incidence of acute and chronic respiratory diseases propels the demand for arterial blood gas test kits.
North America Arterial Blood Gas Kits Market Overview
According to the HF Stats (SM) initiative launched by the Heart Failure Society of America (HFSA) in 2023, 1 in 4 individuals (~25%) are expected to experience HF in their lifetime, a rise from the previous estimate of 1 in 5 individuals (~20%). As per HF Stats, an HFSA database, ~6.7 million Americans over 20 years of age suffer HF, and the prevalence is expected to rise to 8.5 million Americans by 2030. The lifetime risk of HF has increased to 24%, i.e., ~1 in every 4 individuals is projected to suffer from HF in their lifetime. According to the Asthma and Allergy Foundation of America, ~26 million people in the US had asthma in 2022, one of the world's most common respiratory diseases. Respiratory infections cause more severe disease, leading to hospitalizations or death. Mortality is more common in older persons than in younger ones due to age-related issues such as frailty and immunosenescence. Asthma is one of the most common respiratory diseases among senior citizens. According to the 2020 Census, the geriatric population reached 55.8 million (16.8%) of the total US population in 2020, and it is projected to rise significantly during 2012-2050. These individuals need a greater understanding of the impact of respiratory diseases on their health, as patients suffering from respiratory disorders usually experience breathing issues due to oxygen shortage. Arterial blood gas analysis evaluates dissolved oxygen and carbon dioxide content, in the form of partial oxygen pressures (PaO2) and partial carbon dioxide pressures (PaCO2), in the arterial blood of patients. PaCO2 gives information on ventilation status (acute or chronic respiratory failure), while PaO2 provides insights into oxygenation status. The growing prevalence of chronic diseases necessitating arterial blood gas analysis, including respiratory failure, acute respiratory distress syndrome (ARDS), asthma, diabetic ketoacidosis, renal tubular acidosis, heart failure (HF), and congenital metabolic diseases, is the major factor contributing to the largest share of the US in the arterial blood gas kits market. Moreover, the country's well-established position in terms of technological advancements contributes notably to the availability of various arterial blood gas kits and associated technologies.
North America Arterial Blood Gas Kits Market Revenue and Forecast to 2031 (US$ Thousand)
North America Arterial Blood Gas Kits Market Segmentation
The North America arterial blood gas kits market is categorized into syringe type, type, usage, application, needle gauge, syringe volume, end user, and country.
Based on syringe type, the North America arterial blood gas kits market is bifurcated into luer slip syringe and luer lock syringe. The luer lock syringe segment held a larger market share in 2023.
In terms of type, the North America arterial blood gas kits market is bifurcated into vented and non-vented. The vented segment held a larger market share in 2023.
By usage, the North America arterial blood gas kits market is bifurcated into pre-set plunger mode and manual aspiration. The pre-set plunger mode segment held a larger market share in 2023.
Based on application, the North America arterial blood gas kits market is bifurcated into in vitro diagnostics and electrolyte analysis. The in vitro diagnostics segment held a larger market share in 2023. Furthermore, the in vitro diagnostics segment is sub segmented into pH blood gas, oxygen content, and others.
In terms of needle gauge, the North America arterial blood gas kits market is segmented into less than 23G, 23G to 25G, and greater than 25G. The 23G to 25G segment held the largest market share in 2023.
Based on syringe volume, the North America arterial blood gas kits market is segmented into 1ml, 3ml, and others. The 3ml segment held the largest market share in 2023.
By end user, the North America arterial blood gas kits market is categorized into hospitals & clinics, diagnostic laboratories, and others. The hospitals & clinics held the largest market share in 2023.
Based on country, the North America arterial blood gas kits market is segmented into the US, Canada, and Mexico. The US dominated the North America arterial blood gas kits market share in 2023.
Radiometer Medical ApS, Vyaire Medical Inc, Opti Medical Systems, Siemens Healthineers AG, AdvaCare Pharma USA LLC, Becton Dickinson and Co, ICU Medical Inc, SunMed Group Holdings LLC (AirLife), Trudell Healthcare Solutions Inc, SARSTEDT AG & Co KG, and Lepu Medical Technology Beijing Co Ltd. are among the leading companies operating in the North America arterial blood gas kits market.